RESUMEN
Existence of humoral immunity has been previously demonstrated in malignant ascitic fluids. However, only a limited number of immunogenic tumor-associated antigens (TAAs) were identified, and few of which are associated with ovarian cancer. Here, we identified salt-inducible kinase 3 (SIK3) as a TAA through screening of a random peptide library in the phage display system. Overexpression of SIK3 markedly promoted cell proliferation, attenuated p21(Waf/Cip1) and p27(Kip) expressions in low-grade OVCAR3 cells, and permitted the cells to grow in mice. Decrease in SIK3 expression in high-grade SK-OV3 cells consistently demonstrated its tumorigenic potency by modulating the protein levels of cell cycle regulators. When the expressions of SIK3 and CA125 were compared in cancer tissues, immunohistochemical (IHC) studies indicated that cytoplasm-localized SIK3 was highly expressed in 55% of the ovarian cancer samples. In contrast, it was rarely detected in adenomyosis, leiomyoma and normal ovary tissues, showing its higher specificity (97%) to CA125 (65%) in ovarian cancer. Moreover, experiments using pharmacological inhibitors to block SIK3-induced p21(Waf/Cip1) expression revealed that activation of c-Src and phosphoinositide-3-kinase were critically required for its biological activity, suggesting that they are the downstream signaling mediators of SIK3. These data were further supported by IHC studies, showing coexpression of c-Src with SIK3 in 85% of the ovarian tumor samples stained positive for SIK3. Collectively, our findings indicate that SIK3 is a novel ovarian TAA. Overexpression of SIK3 promotes G1/S cell cycle progression, bestows survival advantages to cancer cells for growth and correlates the clinicopathological conditions of patients with ovarian cancer.
Asunto(s)
Antígenos de Neoplasias/fisiología , Neoplasias Ováricas/etiología , Proteínas Quinasas/fisiología , Proteínas Quinasas Activadas por AMP/fisiología , Animales , Antígenos de Neoplasias/análisis , Ciclo Celular , Línea Celular Tumoral , Proliferación Celular , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/genética , Femenino , Genes src , Humanos , Masculino , Ratones , Neoplasias Ováricas/inmunología , Neoplasias Ováricas/patología , Proteínas Quinasas/análisisRESUMEN
We report further expansion of the structure activity relationship (SAR) on the triaryl bis sulfone class of compounds (I), which are potent CB(2) receptor ligands with excellent selectivity over the CB(1) receptor. This study was extended to B ring changes, followed by simultaneous optimization of the A-, B-, and C-rings. Compound 42 has excellent CB(2) potency, selectivity and rat exposure.
Asunto(s)
Receptor Cannabinoide CB2/efectos de los fármacos , Sulfonas/química , Sulfonas/farmacología , Animales , Ligandos , Ratas , Receptor Cannabinoide CB2/metabolismo , Relación Estructura-Actividad , Sulfonas/metabolismoRESUMEN
CD2AP, an adapter protein containing multiple SH3 domains, plays a critical role in kidney function. Mice lacking CD2AP die soon after birth because of kidney failure. In the kidney, CD2AP is expressed in glomerular podocytes, which suggests that it may play a role in a specialized adhesion complex known as the slit diaphragm. One of the major components of the slit diaphragm is nephrin, a podocyte-specific protein. Here we demonstrate that CD2AP localizes to the slit diaphragm in podocytes using immunoelectron microscopy and that nephrin and CD2AP co-immunoprecipitate from a podocyte cell line. The specificity of this interaction was verified by mapping studies, which demonstrated that a novel domain at the C terminus of CD2AP interacts with the C-terminal portion of the nephrin cytoplasmic domain. These studies lend further support to the idea that CD2AP plays a role in the structural integrity of the slit diaphragm.
Asunto(s)
Glomérulos Renales/metabolismo , Proteínas/metabolismo , Proteínas Adaptadoras Transductoras de Señales , Animales , Sitios de Unión/genética , Línea Celular , Proteínas del Citoesqueleto , Uniones Intercelulares/metabolismo , Glomérulos Renales/citología , Glomérulos Renales/ultraestructura , Proteínas de la Membrana , Ratones , Ratones Noqueados , Microscopía Inmunoelectrónica , Mutación , Pruebas de Precipitina , Unión Proteica , Proteínas/química , Proteínas/genéticaRESUMEN
The NK1 and NK2 receptor activity of a series of 5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)-4(Z)-(methoxyimino)pentyl-1-piperidines was evaluated. Compounds 11d, 11e, 11f, 12a, and 12k were found to be our most potent inhibitors.
Asunto(s)
Antagonistas del Receptor de Neuroquinina-1 , Piperidinas/síntesis química , Receptores de Neuroquinina-2/antagonistas & inhibidores , Piperidinas/farmacología , Relación Estructura-ActividadRESUMEN
Functional probing of the backbone of the Sanofi NK2 antagonist SR 48968 has resulted in the discovery of two new classes of NK1/NK2 dual antagonists: the diamine class and the oxime class. The addition of the amino or the oxime functional group results in the reversal of the stereochemical preference of the NK2 receptor.
Asunto(s)
Benzamidas/química , Benzamidas/síntesis química , Diaminas/síntesis química , Antagonistas del Receptor de Neuroquinina-1 , Oximas/síntesis química , Piperidinas/química , Piperidinas/síntesis química , Receptores de Neuroquinina-2/antagonistas & inhibidores , Animales , Benzamidas/farmacología , Diaminas/química , Diaminas/farmacología , Diseño de Fármacos , Cinética , Estructura Molecular , Oximas/química , Oximas/farmacología , Piperidinas/farmacología , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
A series of 5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)-4(Z)- (methoxyimino)pentyl-1-piperazines was prepared and their affinity for the NK1 and NK2 receptors investigated. Compounds 7f, 10o, 10r, and 10s were found to be our most potent inhibitors.
Asunto(s)
Antagonistas del Receptor de Neuroquinina-1 , Piperazinas/síntesis química , Receptores de Neuroquinina-2/antagonistas & inhibidores , Animales , Cinética , Estructura Molecular , Piperazinas/química , Piperazinas/farmacología , Relación Estructura-ActividadRESUMEN
CD2-associated protein (CD2AP) is an 80-kilodalton protein that is critical for stabilizing contacts between T cells and antigen-presenting cells. In CD2AP-deficient mice, immune function was compromised, but the mice died at 6 to 7 weeks of age from renal failure. In the kidney, CD2AP was expressed primarily in glomerular epithelial cells. Knockout mice exhibited defects in epithelial cell foot processes, accompanied by mesangial cell hyperplasia and extracellular matrix deposition. Supporting a role for CD2AP in the specialized cell junction known as the slit diaphragm, CD2AP associated with nephrin, the primary component of the slit diaphragm.
Asunto(s)
Glomérulos Renales/metabolismo , Glomérulos Renales/ultraestructura , Síndrome Nefrótico/congénito , Proteínas/metabolismo , Proteínas Adaptadoras Transductoras de Señales , Animales , Membrana Basal/ultraestructura , Proteínas del Citoesqueleto , Células Epiteliales/metabolismo , Células Epiteliales/ultraestructura , Proteínas de la Matriz Extracelular/metabolismo , Mesangio Glomerular/metabolismo , Mesangio Glomerular/ultraestructura , Uniones Intercelulares/metabolismo , Uniones Intercelulares/ultraestructura , Glomérulos Renales/irrigación sanguínea , Activación de Linfocitos , Proteínas de la Membrana , Ratones , Ratones Noqueados , Microscopía Electrónica , Síndrome Nefrótico/genética , Síndrome Nefrótico/metabolismo , Síndrome Nefrótico/patología , Proteínas/genética , Proteínas Recombinantes de Fusión/metabolismo , Linfocitos T/inmunologíaRESUMEN
Experiments were performed to characterize the pharmacology of Sch 50971 ((+)-trans-4-(4(R)-methyl-3(R)-pyrolidinyl)-1H-imidazole dihydrochloride, CAS 167610-28-8), a novel histamine H3 receptor agonist. The activity of Sch 50971 was compared with that of (R)-alpha-methylhistamine (CAS 75614-87-8), a potent and moderately selective agonist of histamine H3 receptors, in a series of in vitro and in vivo assays. Sch 50971 is a high affinity, selective H3 receptor agonist in vitro and in vivo. Sch 50971 inhibits [3H]-N-alpha-methylhistamine (CAS 673-50-7) binding to the histamine H3 receptor in human brain (Ki = 5.0 nmol/l) and guinea pig brain (Ki = 2.5 nmol/l). Sch 50971 also inhibits electric field stimulated guinea pig ileum contractions (pD2 = 7.47) and decreases [3H]-norepinephrine (CAS 51-41-2) release (pD2 = 7.48) from guinea pig pulmonary artery by activation of presynaptic inhibitory H3 receptors. The in vitro effects of Sch 50971 are antagonized by low concentrations of a selective H3 antagonist, thioperamide (CAS 106243-16-7). Sch 50971 has low affinity (IC50's > 10 mumol/l) for histamine H1, dopamine D1 and D2, serotonin 5-HT2 and muscarinic cholinergic receptors. It also does not exhibit histamine H2-antagonist activity. In guinea pigs and cats, Sch 50971 exhibits in vivo H3 agonist activity. Sch 50971 inhibits sympathetic hypertension evoked by stimulation of the medulla oblongata in anesthetized guinea pigs (ED30 = 0.3 mg/kg i.v., ED30 = 1.0 mg/kg i.d.). Sch 50971 also inhibits the effects of sympathetic nerve stimulation on nasal resistance in cats. In these assays, Sch 50971 exhibits an efficacy and potency comparable to H3-agonist (R)-alpha-methylhistamine. However, under in vivo conditions, Sch 50971 does not exhibit histamine H1-mediated responses that are seen with (R)-alpha-methylhistamine at doses close to those that produce H3 effects. Therefore, Sch 50971 is a novel, potent and selective agonist of histamine H3 receptors with an improved in vitro and in vivo receptor profile selectivity compared with (R)-alpha-methylhistamine.
Asunto(s)
Agonistas de los Receptores Histamínicos/farmacología , Imidazoles/farmacología , Pirrolidinas/farmacología , Resistencia de las Vías Respiratorias/efectos de los fármacos , Animales , Función Atrial , Presión Sanguínea/efectos de los fármacos , Encéfalo/metabolismo , Broncoconstrictores/farmacología , Gatos , Cobayas , Atrios Cardíacos/efectos de los fármacos , Agonistas de los Receptores Histamínicos/farmacocinética , Humanos , Íleon/efectos de los fármacos , Íleon/fisiología , Imidazoles/farmacocinética , Técnicas In Vitro , Masculino , Contracción Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Músculo Liso/metabolismo , Músculo Liso/fisiología , Norepinefrina/metabolismo , Arteria Pulmonar/efectos de los fármacos , Arteria Pulmonar/metabolismo , Pirrolidinas/farmacocinética , Ratas , Receptores Dopaminérgicos/metabolismo , Receptores Histamínicos H1/metabolismo , Receptores Histamínicos H3/metabolismo , Receptores Muscarínicos/metabolismo , Receptores de Serotonina/metabolismo , Mecánica Respiratoria/efectos de los fármacosRESUMEN
By binding to serine-phosphorylated proteins, 14-3-3 proteins function as effectors of serine phosphorylation. The exact mechanism of their action is, however, still largely unknown. Here we demonstrate a requirement for 14-3-3 for Raf-1 kinase activity and phosphorylation. Expression of dominant negative forms of 14-3-3 resulted in the loss of a critical Raf-1 phosphorylation, while overexpression of 14-3-3 resulted in enhanced phosphorylation of this site. 14-3-3 levels, therefore, regulate the stoichiometry of Raf-1 phosphorylation and its potential activity in the cell. Phosphorylation of Raf-1, however, was insufficient by itself for kinase activity. Removal of 14-3-3 from phosphorylated Raf abrogated kinase activity, whereas addition of 14-3-3 restored it. This supports a paradigm in which the effects of phosphorylation on serine as well as tyrosine residues are mediated by inducible protein-protein interactions.
Asunto(s)
Estructura Secundaria de Proteína , Proteínas/química , Proteínas/metabolismo , Proteínas Proto-Oncogénicas c-raf/química , Proteínas Proto-Oncogénicas c-raf/metabolismo , Tirosina 3-Monooxigenasa , Proteínas 14-3-3 , Secuencia de Aminoácidos , Animales , Sitios de Unión , Línea Celular , Cloranfenicol O-Acetiltransferasa/biosíntesis , Clonación Molecular , Glutatión Transferasa , Humanos , Ratones , Modelos Moleculares , Mutagénesis Sitio-Dirigida , Fosforilación , Fosfoserina , Fosfotirosina , Reacción en Cadena de la Polimerasa , Biosíntesis de Proteínas , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes de Fusión/metabolismo , Análisis Espectral , TransfecciónRESUMEN
Extensive structural modification of immepyr (+)-2 led to the discovery of trans-4-methyl-3-imidazoyl pyrrolidine (+/-)-3a as a potent and highly selective H3 agonist. The pyrroline (+/-)-3a was resolved, and its (+) enantiomer, Sch 50971 [(+)-3a], showed a greater separation of H3 and H1 activities in vivo (H3/H1 ratio >> 330) than (R)-alpha-methylhistamine (+)-1 (H3/H1 ratio = 17), the standard H3 agonist.
Asunto(s)
Imidazoles/farmacología , Pirrolidinas/farmacología , Receptores Histamínicos H3/efectos de los fármacos , Animales , Cobayas , Íleon/efectos de los fármacos , Íleon/fisiología , Imidazoles/química , Técnicas In Vitro , Contracción Muscular/efectos de los fármacos , Pirrolidinas/química , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
A series of amidine substituted phenyl-, benzyl-, and phenethylimidazoles based on the known H3 agonist SK&F 91606 (4) has been synthesized and tested as ligands for the histamine H3 receptor. Insertion of a phenyl ring between the imidazole ring and the amidine moiety produces antagonists. The benzyl series was found to be the most potent and was further investigated. Compounds 9c and 18 (entries 5 and 12, Table 1) are potent ligands for the H3 receptor with K(i) values of 16 nM and 7.2 nM respectively. In vivo, both compounds were shown to be equipotent to thioperamide (2), the standard H3 antagonist.
Asunto(s)
Benzamidinas/síntesis química , Antagonistas de los Receptores Histamínicos/síntesis química , Imidazoles/síntesis química , Receptores Histamínicos H3/fisiología , Animales , Benzamidinas/química , Benzamidinas/farmacología , Diseño de Fármacos , Cobayas , Antagonistas de los Receptores Histamínicos/química , Antagonistas de los Receptores Histamínicos/farmacología , Imidazoles/química , Imidazoles/farmacología , Técnicas In Vitro , Indicadores y Reactivos , Cinética , Ligandos , Conformación Molecular , Estructura Molecular , Contracción Muscular/efectos de los fármacos , Contracción Muscular/fisiología , Músculo Liso/efectos de los fármacos , Músculo Liso/fisiología , Receptores Histamínicos H3/efectos de los fármacosRESUMEN
Activation of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) increased steady-state levels of mRNA encoding the major histocompatibility complex (MHC) class II antigen I-A beta and the class II antigen-associated invariant chain (Ii, CD74) in A20 B lymphoma cells and in normal mouse B cells. The increase in Ii mRNA levels appeared to be due to a slight increase in the rate of gene transcription and an increase in the stability of Ii mRNA. The half-life of Ii mRNA increased from 12 h to >24 h following treatment with TPA, as determined by Northern blot analysis following actinomycin D treatment or by the [3H]-uridine pulse-chase method. Interferon-gamma (IFN-gamma), which has been well characterized as a cytokine that induces class II antigens and the Ii, increased Ii expression slightly in A20 cells. However, cotreatment of cells with TPA and IFN-gamma resulted in a block in the TPA-induced increase in Ii expression. Transcription of the Ii gene was minimally affected following treatment with IFN-gamma alone, and cells treated with both TPA and IFN-gamma had the same transcription rate as the control cells. IFN-gamma did, however, block stabilization of Ii mRNA by TPA. Activation of PKC by TPA, which was previously shown to lead to membrane translocation and downregulation, was not inhibited by IFN-gamma. Therefore, IFN-gamma appeared to block a downstream signal transduction pathway activated by PKC that controls stability of Ii mRNA.
Asunto(s)
Antígenos de Neoplasias/genética , Antineoplásicos/uso terapéutico , Interferón gamma/uso terapéutico , Linfoma de Células B/tratamiento farmacológico , ARN Mensajero/efectos de los fármacos , Acetato de Tetradecanoilforbol/farmacología , Animales , Antígenos de Diferenciación de Linfocitos B/genética , Activación Enzimática , Antígenos de Histocompatibilidad Clase II/genética , Isoenzimas/efectos de los fármacos , Linfoma de Células B/patología , Ratones , Ratones Endogámicos BALB C , Proteína Quinasa C/efectos de los fármacos , ARN Mensajero/biosíntesis , Acetato de Tetradecanoilforbol/antagonistas & inhibidores , Transcripción Genética , Células Tumorales CultivadasRESUMEN
Activation of protein kinase C-delta (PKC-delta) by 12-O-tetradecanoylphorbol-13-acetate (TPA) is followed by a gradual decrease in detectable protein 12-24 h later in the mouse B lymphoma cell line A20. Down-regulation is associated with TPA-induced proteolysis and a 50-86% decrease in PKC-delta mRNA 0.5-24 h post-treatment which is due to both a 50% decrease in transcription and accelerated degradation of PKC-delta mRNA as determined using the pulse-chase method. Destabilization of PKC-delta mRNA is also observed when actinomycin D is added to cells pretreated with TPA for 2 h; however, addition of actinomycin D or cycloheximide prior to TPA treatment blocks destabilization. Addition of PKC inhibitors to TPA-treated cells also blocks destabilization of PKC-delta mRNA. Cells treated with TPA for 4 h contain an activity not found in control cells which destabilizes PKC-delta mRNA but not glyceraldehyde-3-phosphate dehydrogenase mRNA in vitro. Addition of TPA to control extracts fails to increase degradation of PKC-delta mRNA in vitro, suggesting that treatment of intact cells is required to induce the synthesis of a factor(s) that destabilizes PKC-delta mRNA. This factor(s) then acts along with transcriptional and post-translational regulatory mechanisms to down-regulate PKC-delta.
Asunto(s)
Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Isoenzimas/biosíntesis , Proteína Quinasa C/biosíntesis , Acetato de Tetradecanoilforbol/farmacología , Transcripción Genética/efectos de los fármacos , Alcaloides , Animales , Benzofenantridinas , Northern Blotting , Línea Celular , Membrana Celular/enzimología , Núcleo Celular/metabolismo , Citosol/enzimología , Dactinomicina/farmacología , Activación Enzimática , Inhibidores Enzimáticos/farmacología , Isoenzimas/metabolismo , Cinética , Linfoma de Células B , Ratones , Naftalenos/farmacología , Fenantridinas/farmacología , Proteína Quinasa C/metabolismo , Proteína Quinasa C-delta , Procesamiento Postranscripcional del ARN/efectos de los fármacos , ARN Mensajero/biosíntesis , Factores de Tiempo , Células Tumorales CultivadasRESUMEN
The invariant chain (Ii, CD74) is a transmembrane glycoprotein that is transiently associated with the MHC class II antigens in the endoplasmic reticulum and in endocytic vesicles. An activator of protein kinase C (PKC), 12-O-tetradecanoyl-1,2-phorbol 13-acetate (TPA), was found to enhance expression of Ii mRNA in the murine B lymphoma cell line, A20, 6-48 hr following treatment. In contrast, TPA did not induce the Ii in NIH 3T3 fibroblasts. TPA addition to either cell line activated PKC. Pretreatment of A20 cells with the PKC inhibitors, staurosporine or chelerythrine chloride, for 5 or 20 min prior to addition of TPA, decreased Ii mRNA levels when compared to cells treated with TPA alone. A 20 min preincubation with the highly specific PKC inhibitor, calphostin C, completely blocked the TPA enhanced expression of the Ii suggesting that activation of PKC was responsible for TPA increased Ii mRNA levels. IFN-gamma also blocked the TPA increased Ii mRNA levels. Constitutive expression of Ii mRNA was decreased by treatment with staurosporine but not chelerythrine chloride or calphostin C, suggesting that non-PKC protein kinases may also be important for maintaining high levels of Ii mRNA in these cells. Western blot analysis using PKC isotype specific antibodies showed that A20 cells express PKC delta abundantly whereas NIH 3T3 cells express primarily PKC alpha. These data suggest that a PKC delta mediated signal transduction pathway plays a crucial role in up-regulation of the Ii.
Asunto(s)
Antígenos de Diferenciación de Linfocitos B/genética , Antígenos de Histocompatibilidad Clase II/genética , Isoenzimas/metabolismo , Linfoma de Células B/genética , Proteína Quinasa C/metabolismo , Células 3T3 , Animales , Secuencia de Bases , Cartilla de ADN/química , Activación Enzimática , Regulación de la Expresión Génica/efectos de los fármacos , Isoenzimas/antagonistas & inhibidores , Ratones , Proteína Quinasa C/antagonistas & inhibidores , Proteína Quinasa C-delta , ARN Mensajero/genética , Transducción de Señal , Acetato de Tetradecanoilforbol/farmacologíaRESUMEN
Employing classical conformational analysis on a known H3 agonist, (R)-alpha-methylhistamine (1), a series of conformationally constrained H3 agonists were proposed and synthesized. Pyrrolidine (+/-)-4a, a compound proposed to mimic the anti-conformation of (R)-alpha-methylhistamine (1), was found to be a potent and selective H3 agonist. The pyrrolidine (+/-)-4a was resolved, and its (+) enantiomer, immepyr [(+)-4a], showed a greater separation of H3 and H1 activities in vivo (H3/H1 ratio >> 550) than (R)-alpha-methylhistamine (1) (H3/H1 ratio = 17), the standard H3 agonist. In fact, no evidence of H1 activity was detected at doses of immepyr [(+)-4a] as high as 100 mg/kg i.v. This pyrrolidine, immepyr [(2R,3S)-(+)-4a], represents, to our knowledge, the first reported cyclic, conformationally restricted analog of histamine to possess selective in vivo H3 agonist activity.
Asunto(s)
Agonistas de los Receptores Histamínicos , Histamina/análogos & derivados , Pirrolidinas/química , Histamina/química , Histamina/farmacología , Conformación MolecularRESUMEN
The H3-histamine receptor provides feedback inhibition of histamine synthesis and release as well as inhibition of other neurotransmitter release. We have characterized this receptor by radioligand binding studies with the H3 agonist N alpha-[3H]methylhistamine ([3H]NAMHA). The results of [3H]NAMHA saturation binding and NAMHA inhibition of [3H]NAMHA binding were consistent with an apparently single class of receptors (KD = 0.37 nM, Bmax = 73 fmol/mg of protein) and competition assays with other agonists and the antagonists impromidine and dimaprit disclosed only a single class of sites. In contrast, inhibition of [3H]NAMHA binding by the specific high affinity H3 antagonist thioperamide revealed two classes of sites (KiA = 5 nM, BmaxA = 30 fmol/mg of protein; KiB = 68 nM, BmaxB = 48 fmol/mg of protein). Burimamide, another antagonist that, like thioperamide, contains a thiourea group, likewise discriminated between two classes of sites. In addition to differences between some antagonist potencies for the two receptors, there is a differential guanine nucleotide sensitivity of the two. The affinity of the H3A receptor for [3H] NAMHA was reduced less than 2-fold, whereas [3H]NAMHA binding to the H3B receptor was undetectable in the presence of guanosine 5'-O-(3-thiotriphosphate). The distinction between H3A and H3B receptor subtypes, the former a high affinity and the latter a low affinity thioperamide site, draws support from published in vitro data.
Asunto(s)
Metilhistaminas/farmacología , Piperidinas/farmacología , Receptores Histamínicos/clasificación , Animales , Sitios de Unión/efectos de los fármacos , Unión Competitiva , Química Encefálica , Burimamida/farmacología , Dimaprit , Guanidinas/farmacología , Guanosina 5'-O-(3-Tiotrifosfato)/farmacología , Histamina/farmacología , Imidazoles/farmacología , Impromidina , Masculino , Ensayo de Unión Radioligante , Ratas , Ratas Endogámicas , Receptores Histamínicos/análisis , Receptores Histamínicos/efectos de los fármacos , Receptores Histamínicos H3 , Tiourea/farmacología , TritioRESUMEN
We have used [3H]N alpha-methylhistamine to characterize H3-binding in the guinea pig brain and to study its tissue distribution. Kinetic and equilibrium binding experiments indicate a single class of high affinity sites in membranes isolated from guinea pig brain tissue (Kd = 0.4 nM, Bmax = 41 fmol/mg of protein). Competition binding experiments have confirmed that this ligand associates with H3-receptors and, under the conditions used in these experiments, does not bind to H1- or H2-receptors. Although there was some binding in the ileum and large intestine, H3-binding was found primarily in the central nervous system.